ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0738

Integrated Behavioral Health Services for Patients with Chronic Musculoskeletal Pain: Rheumatology Provider Perspectives
Abstract Number: 1129

Integrated High-throughput Proteomics and Machine Learning Analysis in Systemic Lupus Erythematosus Patients Identify Distinctive Clinical Profiles and Novel Biomarkers Related to Cardiovascular Risk and Lupus Nephropathy
Abstract Number: 1131

Integrating Genome and Transcriptome-Wide Associations with Real-World Data to Assess Risk for Leukopenia in Patients Taking Azathioprine
Abstract Number: 0658

Integrative Analysis of Cell-Specific Human Endogenous Retrovirus Expression and Host Gene Expression Identifies Associations with Clinical SLE Phenotypes
Abstract Number: 1406

Integrative Multi-omic Phenotyping in Blood Identifies Molecular Signatures and Candidate Biomarkers of ACPA-negative Rheumatoid Arthritis
Abstract Number: 1196

Interaction of Cumulative Inflammation with Smoking and Lipids in Risk Modification of Dementia Among Patients with Rheumatoid Arthritis: A Population-based Cohort Study
Abstract Number: 1132

Interaction of LOC100507053, ADH1B, and ADH1C with Alcohol Consumption for Elevated Serum Urate Levels and Gout in People of European Ethnicity
Abstract Number: 1704

Interaction of Macrophages and Natural Killer Cells in Pathogenesis of HIV-1-Associated Inflammatory Arthritis
Abstract Number: 1692

Interferon Alpha Promotes Ultraviolet Light-Mediated Keratinocyte Apoptosis in a Caspase-8 Dependent Manner via Upregulation of Interferon Regulatory Factor 1
Abstract Number: 0992

Interim Results from the Phase 2 MISSION Study Evaluating Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor for the Treatment of Lupus Nephritis
Abstract Number: 1951

Interleukin 1 Receptor Antagonist Relation to Cardiovascular Disease in Patients with Rheumatoid Arthritis
Abstract Number: 1185

Interleukin-11 Promotes Fibrosis Through Classic and Trans-signaling Pathway in Systemic Sclerosis
Abstract Number: 0578

Interleukin-6 Trans-Signaling Induces Synovial Fibroblast Invasiveness by Utilizing Ets2 Protein
Abstract Number: 1865

Internet-based Enrollment for Myositis Studies Utilizing Patient Self-reported Diagnostic Criteria
Abstract Number: 2204

Interosseous Tendon Inflammation in the Hands: A Novel Feature of Developing Rheumatoid Arthritis? Results from a Large MRI Study in Clinically Suspect Arthralgia

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].